Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer
In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality.
Most Pediatric Cancer Deaths Occur in Regions of Conflict
Almost 60% of all deaths from pediatric cancers occur in regions of armed conflict, according to the results of a study published in The Lancet Oncology.
FDA Approves Bevacizumab Biosimilar
The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis—combating cancer by restricting blood supply to the tumor.
Study Illuminates Disparities in Treatment, Survival in Metastatic Pancreatic Ductal Adenocarcinoma
Investigators may have uncovered factors that may impact the quality of cancer care and outcomes among patients with metastatic pancreatic ductal adenocarcinoma, according to a recent study published by Tsilimigras et al in JNCCN–Journal of the National Comprehensive Cancer Network.
Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al reported activity with the antibody-drug conjugate (ADC) FOR46 in patients with metastatic castration-resistant prostate cancer. As stated by the investigators, “FOR46, a fully human antibody conjugated to monomethyl auristatin E, targets a tumor-selective epitope of CD46, which is overexpressed in metastatic castration-resistant prostate cancer.”
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
Ramy Sedhom and colleagues on Optimizing Cancer Care for Older Adults
Ilana Hellmann: Reflections on a Father’s Cancer Journey
Connor J. Kinslow and colleagues on Breast Implant–Related Cancers
Lorcan Ruane and colleagues on Cardiotoxicity: How Far Have We Come?
Sponsored Content
Sponsored by Lilly Medical Affairs
The Critical Role of Navigators in Improving Access to First-Line Precision Oncology Therapies for Advanced NSCLC
SPONSORED BY BREAST CANCER INDEX® BIOTHERANOSTICS, INC. A HOLOGIC COMPANY
Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making
More Top Stories
New Reports Assess Oncology Workforce Well-Being, Propose Solutions to Address Burnout
Physician burnout has increased significantly in the past decade, and organizational strategies are vital to improve physician well-being, according to new research from ASCO. This compilation includes reports on the state of professional well-being among oncologists in 2023, burnout trends among...
ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma
Investigators have identified a key component inhibiting responses to lenalidomide in patients with multiple myeloma, according to the results of a study recently published in Blood. They identified adenosine deaminase acting on RNA1 (ADAR1) as a novel driver of acquired resistance to lenalidomide...
CMS Expects Between 750,000 to 2 Million to Lose Coverage If ACA Proposal Is Implemented
On March 10, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Marketplace Integrity and Affordability Proposed Rule aimed at addressing improper enrollments in the Affordable Care Act (ACA) Health Insurance Marketplace. This is the first proposed rule released under the new ...
Results Announced From Phase II VERITAC-2 Clinical Trial in Breast Cancer
Arvinas, Inc. and Pfizer Inc. recently announced results from the randomized phase III VERITAC-2 clinical trial (ClinicalTrials.gov identifier NCT05654623) evaluating vepdegestrant monotherapy vs fulvestrant in adults with estrogen receptor–positive, HER2-negative advanced or metastatic breast...
Pediatric ALL or Lymphoblastic Lymphoma: Reduced Induction Dexamethasone and High-Dose Methotrexate
In a UK phase III trial (UKALL 2011) reported in the Journal of Clinical Oncology, Kirkwood et al found that a shorter duration of induction dexamethasone did not reduce steroid-related toxicity and that high-dose methotrexate (HDM) did not reduce central nervous system (CNS) relapse among patients ...
Screening Was Key to the Early Detection of My Prostate Cancer
As a Native American and former president of the Seneca Nation of Indians, I am keenly aware of the disparities in cancer care we face in accessing screening and treatment, which results in worse survival rates compared with those of racial and ethnic populations.1 Native American and Alaska Native ...
Incidence Rates of Colorectal and Pancreatic Cancers Are Rising Most Among Young Adults
The incidence rates of colorectal and pancreatic adenocarcinomas have risen the most among young adults over the past 2 decades, suggesting the need for heightened awareness among clinicians for these diseases in this patient population, according to a report published by Bussetty et al in JAMA...
